Biotech | April 06, 2022
Alvotech and STADA pave way to launching Hukyndra
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
All intellectual-property disputes related to the market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved
The new facility is scheduled to start operation in the first half of 2024
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Drones will be used in the Gurugram and Mumbai region to transport pathology samples
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
Subscribe To Our Newsletter & Stay Updated
